{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:32:42Z","timestamp":1769607162448,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,2]]},"DOI":"10.7759\/cureus.27606","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T13:36:54Z","timestamp":1659447414000},"source":"Crossref","is-referenced-by-count":3,"title":["Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?"],"prefix":"10.7759","author":[{"given":"Michelle","family":"Farinango","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Ansary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya","family":"Dakka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humaira","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muaaz","family":"Umair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratyusha","family":"Muddaloor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeny","family":"Chavarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.20008","article-title":"Polymyalgia rheumatica: an updated review","volume":"87","author":"Mahmood SB","year":"2020","unstructured":"Mahmood SB, Nelson E, Padniewski J, Nasr R. Polymyalgia rheumatica: an updated review. Cleve Clin J Med. 2020, 87:549-56. 10.3949\/ccjm.87a.20008","journal-title":"Cleve Clin J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02450-w","article-title":"A meta-analysis of the epidemiology of giant cell arteritis across time and space","volume":"23","author":"Li KJ","year":"2021","unstructured":"Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021, 23:82. 10.1186\/s13075-021-02450-w","journal-title":"Arthritis Res Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2018.1062","article-title":"Update on treatment of polymyalgia rheumatica","volume":"70","author":"Camellino D","year":"2018","unstructured":"Camellino D, Dejaco C. Update on treatment of polymyalgia rheumatica. Reumatismo. 2018, 70:59-66. 10.4081\/reumatismo.2018.1062","journal-title":"Reumatismo"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.12.005","article-title":"Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review","volume":"50","author":"Akiyama M","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020, 50:521-5. 10.1016\/j.semarthrit.2019.12.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study","volume":"22","author":"Chino K","year":"2019","unstructured":"Chino K, Kondo T, Sakai R, et al.. Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Rheum Dis. 2019, 22:2151-7. 10.1111\/1756-185X.13723","journal-title":"Int J Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay MA","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, Llorca J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009, 61:1454-61. 10.1002\/art.24459","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.09.004","article-title":"Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment","volume":"44","author":"Martinez-Taboada VM","year":"2008","unstructured":"Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine. 2008, 44:207-20. 10.1016\/j.cyto.2008.09.004","journal-title":"Cytokine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.59","article-title":"Current understanding and management of giant cell arteritis and polymyalgia rheumatica","volume":"6","author":"Ghosh P","year":"2010","unstructured":"Ghosh P, Borg FA, Dasgupta B. Current understanding and management of giant cell arteritis and polymyalgia rheumatica. Expert Rev Clin Immunol. 2010, 6:913-28. 10.1586\/eci.10.59","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone JH","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al.. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017, 377:317-28. 10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli M","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, et al.. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann Rheum Dis. 2022, 81:838-44. 10.1136\/annrheumdis-2021-221126","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera R","year":"2021","unstructured":"Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A, Stone JH. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum. 2021, 51:469-76. 10.1016\/j.semarthrit.2021.03.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex169","article-title":"Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica","volume":"56","author":"Carvajal Alegria G","year":"2017","unstructured":"Carvajal Alegria G, Devauchelle-Pensec V, Renaudineau Y, Saraux A, Pers JO, Cornec D. Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica. Rheumatology (Oxford). 2017, 56:1401-6. 10.1093\/rheumatology\/kex169","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132948","article-title":"Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study","volume":"10","author":"Izumi K","year":"2021","unstructured":"Izumi K, Murata O, Higashida-Konishi M, Kaneko Y, Oshima H, Takeuchi T. Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study. J Clin Med. 2021, 10:2948. 10.3390\/jcm10132948","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02377-8","article-title":"Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations","volume":"23","author":"Unizony S","year":"2021","unstructured":"Unizony S, McCulley TJ, Spiera R, et al.. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021, 23:8. 10.1186\/s13075-020-02377-8","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1499-2","article-title":"Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab","volume":"20","author":"Huwart A","year":"2018","unstructured":"Huwart A, Garrigues F, Jousse-Joulin S, et al.. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res Ther. 2018, 20:11. 10.1186\/s13075-017-1499-2","journal-title":"Arthritis Res Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00299-8","article-title":"Inflammatory markers are quickly improved by tocilizumab in early polymyalgia rheumatica and might predict early response to interleukin-6 blockade","volume":"8","author":"Carvajal Alegria G","year":"2021","unstructured":"Carvajal Alegria G, Cornec DY, Renaudineau Y, Saraux A, Devauchelle-Pensec V. Inflammatory markers are quickly improved by tocilizumab in early polymyalgia rheumatica and might predict early response to interleukin-6 blockade. Rheumatol Ther. 2021, 8:751-60. 10.1007\/s40744-021-00299-8","journal-title":"Rheumatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec V","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, et al.. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016, 75:1506-10. 10.1136\/annrheumdis-2015-208742","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","unstructured":"The University of Adelaide JBI. Critical Appraisal Tools. (2022). Accessed. April 15, 2022: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco C","year":"2017","unstructured":"Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017, 13:578-92. 10.1038\/nrrheum.2017.142","journal-title":"Nat Rev Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"van der Geest KS","year":"2014","unstructured":"van der Geest KS, Abdulahad WH, Chalan P, et al.. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014, 66:1927-38. 10.1002\/art.38625","journal-title":"Arthritis Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/99487-is-tocilizumab-effective-and-safe-in-polymyalgia-rheumatica-and-giant-cell-arteritis-with-polymyalgia-rheumatica","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:05Z","timestamp":1707507965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/99487-is-tocilizumab-effective-and-safe-in-polymyalgia-rheumatica-and-giant-cell-arteritis-with-polymyalgia-rheumatica"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.27606","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}